Ontology highlight
ABSTRACT: Introduction
The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR. However, controversy exists regarding the role of AR, particularly in ER + tumors. Enzalutamide, an AR inhibitor that impairs nuclear localization of AR, was used to elucidate the role of AR in preclinical models of ER positive and negative breast cancer.Methods
We examined nuclear AR to ER protein ratios in primary breast cancers in relation to response to endocrine therapy. The effects of AR inhibition with enzalutamide were examined in vitro and in preclinical models of ER positive and negative breast cancer that express AR.Results
In a cohort of 192 women with ER + brea
SUBMITTER: Cochrane DR
PROVIDER: S-EPMC3978822 | biostudies-literature | 2014 Jan
REPOSITORIES: biostudies-literature